Iobenzamic acid

Iobenzamic acid represents a noteworthy compound in the domain of radiographic diagnostics. As an organoiodine molecule, it stands out for its role as a contrast medium, assisting healthcare professionals in obtaining high-resolution, clear radiographic images.

Chemical Characteristics[edit]

The key attribute of iobenzamic acid, like other iodinated contrast agents, is its iodine moiety. Iodine has a unique capability to absorb X-rays effectively, which, when introduced into the body, helps delineate between tissues with different densities, offering enhanced visibility in radiographic imaging^[1].

Clinical Utility[edit]

Due to its radiopaque nature, iobenzamic acid finds a place in an array of diagnostic imaging applications, including:

The intrinsic capacity of iobenzamic acid to amplify contrast between bodily structures paves the way for clearer and more detailed images, thereby facilitating an accurate diagnosis^[2].

Pharmacokinetics[edit]

Upon its administration, iobenzamic acid distributes rapidly within the vascular system and, depending on the imaging procedure, might also penetrate interstitial spaces. Typically, the excretion of iodinated contrast agents is through the renal system, necessitating caution and potential dose modifications in patients with renal insufficiencies^[3].

Safety Profile and Side Effects[edit]

While iobenzamic acid is considered safe for most patients, there are potential side effects and adverse reactions:

Warmth or sensation of heat upon injection
Nausea or vomiting
Flushing

Rare, but more serious side effects could include:

Hypersensitivity or allergic reactions
Contrast-induced nephropathy
Hemodynamic disturbances
It's essential to promptly address any untoward reactions following the administration of the contrast agent^[4].

Conclusion[edit]

Iobenzamic acid, with its distinct properties and efficacy as a contrast medium, has been pivotal in refining the outcomes of diagnostic imaging. Its targeted use, combined with careful patient monitoring, ensures the acquisition of high-quality images with minimal risks.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

References[edit]

Strickland, N. H. (1991). Iodinated contrast media: physical and biological properties. The British Journal of Radiology, 64(767), 923-928.
Van der Molen, A. J., Thomsen, H. S., & Morcos, S. K. (2004). Effect of iodinated contrast media on thyroid function in adults. European Radiology, 14(5), 902-907.
Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1992). Intravascular contrast material administration: guidelines for use and potential complications. Radiographics, 12(1), 173-187.
Thomsen, H. S., Morcos, S. K., & Dawson, P. (2006). Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT: a pooled analysis of two randomized trials. European Radiology, 16(3), 505-511.

↑ Strickland, N. H. (1991). Iodinated contrast media: physical and biological properties. The British Journal of Radiology, 64(767), 923-928.
↑ Van der Molen, A. J., Thomsen, H. S., & Morcos, S. K. (2004). Effect of iodinated contrast media on thyroid function in adults. European Radiology, 14(5), 902-907.
↑ Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1992). Intravascular contrast material administration: guidelines for use and potential complications. Radiographics, 12(1), 173-187.
↑ Thomsen, H. S., Morcos, S. K., & Dawson, P. (2006). Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT: a pooled analysis of two randomized trials. European Radiology, 16(3), 505-511.

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] Strickland, N. H. (1991). Iodinated contrast media: physical and biological properties. The British Journal of Radiology, 64(767), 923-928.

[2] Van der Molen, A. J., Thomsen, H. S., & Morcos, S. K. (2004). Effect of iodinated contrast media on thyroid function in adults. European Radiology, 14(5), 902-907.

[3] Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1992). Intravascular contrast material administration: guidelines for use and potential complications. Radiographics, 12(1), 173-187.

[4] Thomsen, H. S., Morcos, S. K., & Dawson, P. (2006). Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT: a pooled analysis of two randomized trials. European Radiology, 16(3), 505-511.

[1]

[2]

[3]

[4]